Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30878631 | 0.88 | ESR1 (0.40) | ESR1ESR2KMT2AGPR119MTNR1B | |
| SCHEMBL30878596 | 0.85 | PDK2 (0.48) | ESR1ESR2MTNR1BGHSR | |
| SCHEMBL30878565 | 0.78 | CA12 (0.48) | ESR1ESR2GHSR | |
| SCHEMBL30878562 | 0.78 | ESR1 (0.57) | ESR1ESR2KMT2AMTNR1B | |
| SCHEMBL25722286 | 0.78 | ESR1 (0.57) | ESR1ESR2KMT2AMTNR1B | |
| SCHEMBL30878583 | 0.77 | CA12 (0.47) | ESR1ESR2GHSR | |
| SCHEMBL30878515 | 0.75 | RIPK1 (0.45) | ESR1ESR2HDAC1GPR119HRH3 | |
| SCHEMBL30878534 | 0.72 | ESR1 (0.58) | ESR1ESR2KMT2AMTNR1B | |
| SCHEMBL30878560 | 0.71 | ESR1 (0.53) | ESR1ESR2KMT2AMTNR1B | |
| SCHEMBL22145358 | 0.71 | ESR1 (0.45) | ESR1ESR2KMT2AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | ESR1 3946/4885ESR2 1952/4885HDAC6 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.